CervoMed Inc. announced positive initial data from the first 12 weeks of its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia. The results, presented on October 12, 2026, showed a reduction in plasma neurofilament light chain (NfL), a key biomarker of neuronal damage and degeneration.
Key Details
- Biomarker Reduction: Over the first 12 weeks, the mean reduction in plasma NfL levels was approximately 3.1 pg/mL. In a subset of patients with higher baseline NfL levels, the mean reduction was approximately 5.7 pg/mL.
- Upcoming Milestones: The company plans to present 24-week biomarker data at a conference in November 2026, with topline clinical data expected in the first quarter of 2027.
- Safety & Trial Design: Neflamapimod was generally well tolerated with no new safety signals identified. The Phase 2a trial has enrolled 25 participants in a 36-week study.